Mara Goldstein
Stock Analyst at Mizuho
(2.55)
# 2,207
Out of 5,128 analysts
69
Total ratings
48.08%
Success rate
14.25%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Mara Goldstein
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KURA Kura Oncology | Maintains: Outperform | $32 → $30 | $9.97 | +200.90% | 3 | May 19, 2025 | |
| IOVA Iovance Biotherapeutics | Maintains: Outperform | $30 → $10 | $2.77 | +261.01% | 5 | May 12, 2025 | |
| VSTM Verastem | Maintains: Outperform | $9 → $8 | $7.64 | +4.71% | 7 | Apr 9, 2025 | |
| RCUS Arcus Biosciences | Maintains: Buy | $51 → $42 | $23.20 | +81.03% | 4 | Jan 30, 2024 | |
| XNCR Xencor | Maintains: Buy | $59 → $50 | $14.95 | +234.45% | 2 | Jan 22, 2024 | |
| SNDX Syndax Pharmaceuticals | Initiates: Buy | $45 | $22.11 | +103.53% | 1 | Dec 22, 2023 | |
| INCY Incyte | Maintains: Neutral | $82 → $77 | $110.57 | -30.36% | 5 | Dec 14, 2023 | |
| ERAS Erasca | Maintains: Buy | $8 → $7 | $5.17 | +35.40% | 3 | Nov 29, 2023 | |
| FATE Fate Therapeutics | Maintains: Buy | $12 → $8 | $1.11 | +620.72% | 5 | Nov 20, 2023 | |
| NKTR Nektar Therapeutics | Reiterates: Neutral | $90 | $43.51 | +106.85% | 3 | Aug 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $3.5 | $7.10 | -50.70% | 5 | Jun 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $360 | $2.50 | +14,300.00% | 2 | Apr 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $10 → $20 | $8.33 | +140.10% | 2 | Apr 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $130 | $108.60 | +19.71% | 2 | Apr 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $4 → $2 | $4.30 | -53.49% | 6 | Mar 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $18 → $12 | $1.95 | +515.38% | 3 | Mar 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $14 → $20 | $65.42 | -69.43% | 3 | Sep 6, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $34 → $48 | $9.05 | +430.39% | 5 | Jul 8, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $27.76 | - | 2 | Apr 17, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $12 → $14 | $5.83 | +140.14% | 1 | Oct 12, 2017 |
Kura Oncology
May 19, 2025
Maintains: Outperform
Price Target: $32 → $30
Current: $9.97
Upside: +200.90%
Iovance Biotherapeutics
May 12, 2025
Maintains: Outperform
Price Target: $30 → $10
Current: $2.77
Upside: +261.01%
Verastem
Apr 9, 2025
Maintains: Outperform
Price Target: $9 → $8
Current: $7.64
Upside: +4.71%
Arcus Biosciences
Jan 30, 2024
Maintains: Buy
Price Target: $51 → $42
Current: $23.20
Upside: +81.03%
Xencor
Jan 22, 2024
Maintains: Buy
Price Target: $59 → $50
Current: $14.95
Upside: +234.45%
Syndax Pharmaceuticals
Dec 22, 2023
Initiates: Buy
Price Target: $45
Current: $22.11
Upside: +103.53%
Incyte
Dec 14, 2023
Maintains: Neutral
Price Target: $82 → $77
Current: $110.57
Upside: -30.36%
Erasca
Nov 29, 2023
Maintains: Buy
Price Target: $8 → $7
Current: $5.17
Upside: +35.40%
Fate Therapeutics
Nov 20, 2023
Maintains: Buy
Price Target: $12 → $8
Current: $1.11
Upside: +620.72%
Nektar Therapeutics
Aug 7, 2023
Reiterates: Neutral
Price Target: $90
Current: $43.51
Upside: +106.85%
Jun 16, 2023
Reiterates: Neutral
Price Target: $3.5
Current: $7.10
Upside: -50.70%
Apr 24, 2023
Reiterates: Buy
Price Target: $360
Current: $2.50
Upside: +14,300.00%
Apr 19, 2023
Upgrades: Buy
Price Target: $10 → $20
Current: $8.33
Upside: +140.10%
Apr 10, 2023
Reiterates: Buy
Price Target: $130
Current: $108.60
Upside: +19.71%
Mar 28, 2023
Maintains: Neutral
Price Target: $4 → $2
Current: $4.30
Upside: -53.49%
Mar 8, 2023
Maintains: Buy
Price Target: $18 → $12
Current: $1.95
Upside: +515.38%
Sep 6, 2019
Reiterates: Overweight
Price Target: $14 → $20
Current: $65.42
Upside: -69.43%
Jul 8, 2019
Downgrades: Neutral
Price Target: $34 → $48
Current: $9.05
Upside: +430.39%
Apr 17, 2018
Downgrades: Neutral
Price Target: n/a
Current: $27.76
Upside: -
Oct 12, 2017
Maintains: Overweight
Price Target: $12 → $14
Current: $5.83
Upside: +140.14%